Evidence map›Paper›PMID 35522148›Full record

ArticleHaematologica2023

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas.

Cristina Lopez, Nikolai Schleussner, Stephan H Bernhart, Kortine Kleinheinz, Stephanie Sungalee, Henrike L Sczakiel, Helene Kretzmer, Umut H Toprak, Selina Glaser, Rabea Wagener and 23 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Haematologica · 2023
    Article
4 · The record

Corrections and comments

  • Commented on by
    2023
5 · Who and what money

Authors and funding

33 authors at 19 institutions in 5 countries.

Cristina LopezInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081, Germany; Institute of Human Genetics, Christian-Albrechts-University, Kiel, 24105.
Nikolai SchleussnerMax-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany; Hematology, Oncology and Tumor Immunology, Charite - Universitatsmedizin Berlin, Berlin, 12200, Germany, and Experimental and Clinical Research Center, a joint cooperation between the MDC and the Charite, Berlin, 13125.
Stephan H BernhartInterdisciplinary Center for Bioinformatics, University of Leipzig, Leipzig, 04107, Germany; Bioinformatics Group, Department of Computer, University of Leipzig, Leipzig, 04107, Germany; Transcriptome Bioinformatics, LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig, 04107.
Kortine KleinheinzDepartment for Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg, 69120.
Stephanie SungaleeEMBL Heidelberg, Genome Biology Unit, Heidelberg, 69117.
Henrike L SczakielMax-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany; Hematology, Oncology and Tumor Immunology, Charite - Universitatsmedizin Berlin, Berlin, 12200, Germany, and Experimental and Clinical Research Center, a joint cooperation between the MDC and the Charite, Berlin, 13125.
Helene KretzmerInterdisciplinary Center for Bioinformatics, University of Leipzig, Leipzig, 04107, Germany; Bioinformatics Group, Department of Computer, University of Leipzig, Leipzig, 04107, Germany; Transcriptome Bioinformatics, LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig, 04107, Germany; Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin.
Umut H ToprakBioinformatics and Omics Data Analytics (B240), German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, 69120, Germany; Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Division of Neuroblastoma Genomics (B087, German Cancer Research Center (DKFZ), Heidelberg, 69120.
Selina GlaserInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081.
Rabea WagenerInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081, Germany; Institute of Human Genetics, Christian-Albrechts-University, Kiel, 24105.
Ole AmmerpohlInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081, Germany; Institute of Human Genetics, Christian-Albrechts-University, Kiel, 24105.
Susanne BensInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081, Germany; Institute of Human Genetics, Christian-Albrechts-University, Kiel, 24105.
Maciej GiefingInstitute of Human Genetics, Christian-Albrechts-University, Kiel, 24105, Germany; Institute of Human Genetics, Polish Academy of Sciences, Poznan, 60-479, Poland.
Juan C Gonzalez SanchezBioQuant and Biochemie Zentrum Heidelberg (BZH), Heidelberg University, Heidelberg, 69120.
Gordana ApicBioQuant and Biochemie Zentrum Heidelberg (BZH), Heidelberg University, Heidelberg, 69120.
Daniel HubschmannGerman Cancer Consortium (DKTK), Heidelberg, 69120, Germany; Heidelberg Institute of Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, 69120, Germany; Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, 69120.
Martin JanzMax-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany; Hematology, Oncology and Tumor Immunology, Charite - Universitatsmedizin Berlin, Berlin, 12200, Germany, and Experimental and Clinical Research Center, a joint cooperation between the MDC and the Charite, Berlin, 13125.
Markus KreuzInstitute for Medical Informatics Statistics and Epidemiology, Leipzig, 04107.
Anja MottokInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081.
Judith M MullerKlinik für Urologie und Zentrale Klinische Forschung, Klinikum der Albert-Ludwigs-Universitat Freiburg, Freiburg, 79104.
Julian SeufertBioinformatics and Omics Data Analytics (B240), German Cancer Research Center (DKFZ), Heidelberg, 69120.
Steve HoffmannInterdisciplinary Center for Bioinformatics, University of Leipzig, Leipzig, 04107, Germany; Bioinformatics Group, Department of Computer, University of Leipzig, Leipzig, 04107, Germany; Transcriptome Bioinformatics, LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig, 04107, Germany; Leibniz Institute on Ageing-Fritz Lipmann Institute (FLI), Computational Biology, Jena, 07745.
Jan O KorbelEMBL Heidelberg, Genome Biology Unit, Heidelberg, 69117.
Robert B RussellBioQuant and Biochemie Zentrum Heidelberg (BZH), Heidelberg University, Heidelberg, 69120.
Roland SchuleKlinik für Urologie und Zentrale Klinische Forschung, Klinikum der Albert-Ludwigs-Universitat Freiburg, Freiburg, 79104, Germany; BIOSS Centre of Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, 79104.
Lorenz TrumperDepartment of Hematology and Oncology, Georg-August-University of Gottingen, Gottingen, 37075.
Wolfram KlapperHematopathology Section, Christian-Albrechts-University, Kiel, 24105.
Bernhard RadlwimmerDivision of Molecular Genetics, German Cancer Research Center (DKFZ), 69120, Heidelberg.
Peter LichterDivision of Molecular Genetics, German Cancer Research Center (DKFZ), 69120, Heidelberg.
Ralf KuppersInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, 45147, Germany, and German Cancer Consortium (DKTK).
Matthias SchlesnerBioinformatics and Omics Data Analytics (B240), German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany; Biomedical Informatics, Data Mining and Data Analytics, Augsburg University, Augsburg, 86159.
Stephan MathasMax-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany; Hematology, Oncology and Tumor Immunology, Charite - Universitatsmedizin Berlin, Berlin, 12200, Germany, and Experimental and Clinical Research Center, a joint cooperation between the MDC and the Charite, Berlin, 13125.
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081, Germany; Institute of Human Genetics, Christian-Albrechts-University, Kiel, 24105.
Heidelberg University · DEInstitute of Human Genetics · PLCharité - Universitätsmedizin Berlin · DEEuropean Bioinformatics Institute · GBGerman Cancer Research Center · DEHeidelberg University · USUniversity Medical Center · USUniversity Medical Center Freiburg · DEAugsburg University · USChristian-Albrechts-Universität zu Kiel · DEDeutschen Konsortium für Translationale Krebsforschung · DEInstitute for Medical Informatics and Biostatistics · CHLeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DELeipzig University · DELife University · USMax Delbrück Center · DEPolish Academy of Sciences · PLUniversität Ulm · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone methylation-modifiers, such as EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we investigated whole genome and transcriptome data of 186 mature B-cell lymphomas sequenced in the ICGC MMML-Seq project. Besides confirming common alterations of KMT2D (47% of cases), EZH2 (17%), SETD1B (5%), PRDM9 (4%), KMT2C (4%), and SETD2 (4%), also identified by prior exome or RNA-sequencing studies, we here found recurrent alterations to KDM4C in chromosome 9p24, encoding a histone demethylase. Focal structural variation was the main mechanism of KDM4C alterations, and was independent from 9p24 amplification. We also identified KDM4C alterations in lymphoma cell lines including a focal homozygous deletion in a classical Hodgkin lymphoma cell line. By integrating RNA-sequencing and genome sequencing data we predict that KDM4C structural variants result in loss-offunction. By functional reconstitution studies in cell lines, we provide evidence that KDM4C can act as a tumor suppressor. Thus, we show that identification of structural variants in whole genome sequencing data adds to the comprehensive description of the mutational landscape of lymphomas and, moreover, establish KDM4C as a putative tumor suppressive gene recurrently altered in subsets of B-cell derived lymphomas.

Indexed as

LymphomaLymphoma, B-CellHistone DemethylasesHistone-Lysine N-MethyltransferaseHistonesHomozygoteHumansJumonji Domain-Containing Histone DemethylasesRNASequence DeletionWhole Genome SequencingHistone DemethylasesHistone-Lysine N-MethyltransferaseHistonesJumonji Domain-Containing Histone DemethylasesKDM4C protein, humanPRDM9 protein, humanRNA

Identifiers

PMID35522148
PMCPMC9890021
OpenAlexW4229069951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.